The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

Launched by JAVIER TOLEDO · Dec 3, 2024

Keywords

ClinConnect Summary

The CCANED-CIPHER study is focused on developing a new blood test that uses artificial intelligence (AI) to help detect cancer early and monitor how well treatments are working. The goal is to identify specific markers in blood cells that can tell the difference between healthy individuals and those with certain types of cancer, including breast, lung, pancreatic, prostate, ovarian, colorectal cancers, glioblastoma, and liver cancer. This study is designed to be safe and non-invasive, meaning it won’t require any surgical procedures and will rely on blood samples instead.

To participate in this study, you need to be an adult aged 40 or older with a confirmed diagnosis of one of the specified cancers. You should not be pregnant or have any active infections, and certain medications might need to be paused before participating. If you join, you'll provide blood samples at different times to help researchers gather important information about your condition and treatment response. This study is not yet recruiting participants, but it aims to improve cancer diagnosis and treatment monitoring for many patients in the future.

Gender

ALL

Eligibility criteria

• • Phase 1 (Common Cancer Early Detection - CCANED)
• Inclusion Criteria:
• • Age: Adults aged 40 years or older.
• • Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.
• Exclusion Criteria:
• • Currently pregnant.
• • Presence of any active infectious diseases.
• • Use of anticoagulant or antiplatelet drugs within the past 2 weeks.
• • Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.
• • Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)
• Inclusion Criteria:
• • Adults aged 40 years or older.
• • Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)
• • Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).
• Exclusion Criteria:
• • Presence of another malignancy unless it has been in remission for at least 5 years.
• • Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.